首页> 外文期刊>Wound repair and regeneration: official publication of the Wound Healing Society [and] the European Tissue Repair Society >Multicenter, randomized controlled, observer-blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetes-ProNOx1 study
【24h】

Multicenter, randomized controlled, observer-blinded study of a nitric oxide generating treatment in foot ulcers of patients with diabetes-ProNOx1 study

机译:多中心、随机对照盲法研究一氧化氮生成治疗足溃疡的患者diabetes-ProNOx1研究

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this multicenter, prospective, observer-blinded, parallel group, randomized controlled trial was to assess the safety and efficacy of EDX110, a nitric oxide generating medical device, in the treatment of diabetic foot ulcers in a patient group reflecting "real world" clinical practice compared against optimal standard care. Participants were recruited from ten hospital sites in multidisciplinary foot ulcer clinics. The ulcers were full thickness, with an area of 25-2,500 mm(2) and either a palpable pedal pulse or ankle brachial pressure index 0.5. Infected ulcers were included. Treatment lasted 12 weeks, or until healed, with a 12-week follow-up period. Both arms were given optimal debridement, offloading and antimicrobial treatment, the only difference being the fixed used of EDX110 as the wound dressing in the EDX110 group. 135 participants were recruited with 148 ulcers (EDX110-75; Control-73), 30% of which were clinically infected at baseline. EDX110 achieved its primary endpoint by attaining a median Percentage Area Reduction of 88.6% compared to 46.9% for the control group (p = 0.016) at 12 weeks in the intention-to-treat population. There was no significant difference between wound size reduction achieved by EDX110 after 4 weeks and the wound size reduction achieved in the control group after 12 weeks. EDX110 was well tolerated. Thirty serious adverse events were reported (12 in the EDX110 group, of which 4 were related to the ulcer; 18 in the control group, of which 10 were related and 1 possibly related to the ulcer), with significant reduction in serious adverse events related to the ulcer in EDX group. There was no significant difference in adverse events. This study, in a real world clinical foot ulcer population, demonstrates the ability of EDX110 to improve healing, as measured by significantly reducing the ulcer area, compared to current best clinical practice.
机译:的目的多中心、前瞻性盲法,平行组,随机对照试验是评估和安全EDX110功效,一氧化氮生成医疗设备,治疗糖尿病足溃疡病人组反映“真实世界”临床实践而对最优标准治疗。在多学科的脚十医院网站溃疡诊所。面积25 - 2500毫米(2)和一个明显的踏板脉冲或踝臂的压力指数比;治疗持续12周,或者直到痊愈12周的随访期。最佳清创术,卸载和抗菌素治疗,唯一的区别是固定的EDX110作为伤口敷料的使用EDX110组。与148年溃疡(edx110 - 75;在基线临床感染。通过获得EDX110实现了主要终点平均面积减少88.6%相比,对照组为46.9% (p =0.016)在12周意向处理人口。通过EDX110减少伤口大小之间后4周和伤口的大小减少对照组12周后。EDX110耐受性良好。事件被报道(12 EDX110组4被有关溃疡;对照组,其中10个是相关的和1可能与溃疡),意义重大减少相关的严重不良事件EDX组的溃疡。不同的不良事件。真实世界临床人口足部溃疡,演示了EDX110改善的能力愈合,以大大减少溃疡面积,而当前的最佳临床练习。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号